About: Third Trimester Placentas of SARS‐CoV‐2‐Positive Women: Histomorphology, including Viral Immunohistochemistry and in Situ Hybridization

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Third Trimester Placentas of SARS‐CoV‐2‐Positive Women: Histomorphology, including Viral Immunohistochemistry and in Situ Hybridization Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Third Trimester Placentas of SARS‐CoV‐2‐Positive Women: Histomorphology, including Viral Immunohistochemistry and in Situ Hybridization
Creator	Chen, Xiaowei Smithgall, Marie Mourad, Mirella Cimic, Adela Debelenko, Larisa Hamele-Bena, Diane Liu-Jarin, Xiaolin
Source	Medline; PMC
abstract	AIMS: The wide‐variety of affected organ‐systems associated with SARS‐CoV‐2 infection highlights the need for tissue‐specific evaluation. We compared placentas from SARS‐CoV‐2‐positive and negative women in our hospital in New York City, which became the epicenter of the COVID‐19 pandemic in March 2020. While some limited studies have been published on placentas from SARS‐CoV‐2‐positive women to date, this study, in addition to describing histomorphology, utilizes in‐situ hybridization (ISH) for the S‐gene encoding the spike‐protein and immunohistochemistry (IHC) with the monoclonal‐SARS‐CoV‐2 spike‐antibody 1A9 for placental evaluation. METHODS AND RESULTS: In this study, 51 singleton, third‐trimester placentas from SARS‐CoV‐2‐positive women and 25 singleton, third‐trimester placentas from SARS‐CoV‐2‐negative women were examined histomorphologically using the Amsterdam Criteria as well as with ISH and/or IHC. Corresponding clinical findings and neonatal outcomes also were recorded. While no specific histomorphologic changes related to SARS‐CoV‐2 were noted in the placentas, evidence of maternal/fetal vascular malperfusion was identified, with placentas from SARS‐CoV‐2‐positive women significantly more likely to show villous agglutination (p=0.003) and subchorionic thrombi (p=0.026) than placentas from SARS‐CoV‐2‐negative women. No evidence of direct viral involvement was identified using ISH and IHC. CONCLUSIONS: In this study, third trimester placentas from SARS‐CoV‐2‐positive women were more likely to show evidence of maternal/fetal vascular malperfusion; however, no evidence of direct viral involvement or vertical transmission was noted by ISH and IHC.
has issue date	2020-07-21(xsd:dateTime)
bibo:doi	10.1111/his.14215
bibo:pmid	32692408
has license	no-cc
sha1sum (hex)	16b9eee45ec9b13293df26d77648429d5f578d28
schema:url	https://doi.org/10.1111/his.14215
resource representing a document's title	Third Trimester Placentas of SARS‐CoV‐2‐Positive Women: Histomorphology, including Viral Immunohistochemistry and in Situ Hybridization
has PubMed Central identifier	PMC7405484
has PubMed identifier	32692408
schema:publication	Histopathology
resource representing a document's body	covid:16b9eee45ec9b13293df26d77648429d5f578d28#body_text
is schema:about of	named entity 'histomorphology' named entity 'addition' named entity 'Hybridization' named entity 'HOSPITAL' named entity 'pandemic' named entity 'study' named entity 'New York City' named entity 'SARS-CoV-2' named entity 'ISH' named entity 'SARS-CoV-2' named entity 'IHC' named entity 'organ' named entity 'March 2020' named entity 'histomorphology' named entity 'Positive Women' named entity 'Placentas' named entity 'Histomorphology' named entity 'SARS-CoV-2' named entity 'Immunohistochemistry' named entity 'published' named entity 'sample size' named entity 'Remdesivir' named entity 'fibrin' named entity 'IHC' named entity 'villi' named entity 'gestational age' named entity 'in-situ hybridization' named entity 'umbilical cords' named entity 'preeclampsia' named entity 'placental' named entity 'asymptomatic' named entity 'thrombi' named entity 'SARS' named entity 'placental pathology' named entity 'tocilizumab' named entity 'subchorionic' named entity 'azithromycin' named entity 'malperfusion' named entity 'percentile' named entity 'thrombi' named entity 'ISH' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'IHC' named entity 'SARS-CoV' named entity 'hypothyroidism' named entity 'fetal' named entity 'avascular' named entity 'placental' named entity 'pregnant women' named entity 'SARS-CoV-2' named entity 'statistically significant' named entity 'preterm delivery' named entity 'sore throat' named entity 'immunohistochemistry' named entity 'intubation' named entity 'ISH' named entity 'neonates' named entity 'morphology' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'etiology' named entity 'fever' named entity 'preterm labor' named entity 'infarction' named entity 'villous' named entity 'morbidity' named entity 'SARS' named entity 'intrauterine growth restriction' named entity 'in-situ hybridization' named entity 'infection' named entity 'SARS-CoV-2' named entity 'fibrotic' named entity 'SARS-CoV' named entity 'neonates'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software